Molecular determinants of neuroprotection in blood-brain interfaces of the cynomolgus monkey

Abstract

The blood-brain barrier (BBB) formed by the cerebral microvessel endothelium and the blood-CSF barrier (BCSFB) formed by the choroid plexus epithelium impact the cerebral bioavailability of drugs and endogenous molecules that contribute to neuroinflammatory and neurodegenerative diseases. Species specificities in tight junction proteins and efflux transporters governing the barrier functions of these interfaces hamper the direct translation of pharmacokinetic and pathophysiological data from rodents to human. We defined the molecular composition of tight junctions and identified the efflux transporters present at the BBB and BCSFB of cynomolgus monkey to assess whether this species is a relevant alternative to rodents. Choroid plexuses, cerebral microvessels, cortex and cerebellum were isolated from adult cynomolgus monkeys, and analysed by RT-qPCR and immunohistochemistry. Results were compared with data available in the literature for rat and human. In monkeys as in rat and human, claudin-5 in the BBB and claudin-1, -2, -3 in the BCSFB were landmark tight junction proteins. ABCB1 was strictly associated with the BBB, and ABCC1 was predominant at the BCSFB compared to the BBB. The monkey, like human, differed from rat by the localization of ABCG2 protein in choroidal vessels, a low expression of ABCC4 and SLC22A8 in the BBB, and the presence of SLC47A1 at the BCSFB. While the main characteristics of brain barriers are common to all three species, cynomolgus monkey and human share specificities in the expression and localization of selected claudins and efflux transporters that are not met in rat.

Introduction

The blood-brain interfaces protect the brain from blood-borne deleterious molecules, and coupled with cerebrospinal fluid (CSF) circulation, they maintain the homeostasis necessary for normal brain function. They include the blood-brain barrier proper (BBB), located at the endothelium of the cerebral microvessels and larger vessels, and the blood-CSF barrier (BCSFB) formed by the epithelium of the choroid plexuses which are located within the brain ventricles. The arachnoid membrane located downstream of the CSF flow also forms a barrier between the outer CSF and the blood. To some extent, the pericytes and astrocytes appended to the cerebral microvessels participate to the establishment of the barrier properties associated with the cerebral endothelium. The barrier phenotype of these interfaces results primarily from the presence of continuous tight junctions that seal the barrier cells together and prevent the non-specific paracellular diffusion of blood-borne molecules. Specific claudins, occludin and adaptor tight junction proteins make up these tight junctions. Multispecific efflux transporters that restrict blood-to-brain/CSF, or favor brain/CSF-to-blood, fluxes across barrier cells also contribute to this phenotype. Three families of ATP-binding Cassette (ABC) transporters, ABCB, ABCC and ABCG, and selected solute carriers (SLC), mainly of the SLC22, SLCO, and SLC47 families are especially involved in these efflux processes (Strazielle and Ghersi-Egea, 2013).

These different barriers mechanisms prevent blood-borne toxic molecules from entering the central nervous system (CNS), and participate in the elimination of potentially deleterious cerebral endogenous compounds, thus contributing to cerebral homeostasis. Unsurprisingly, dysfunctions of brain barriers are involved in the pathophysiology of various degenerative and inflammatory CNS diseases (Hubert et al., 2019; Sweeney et al., 2019). The barrier mechanisms also strongly impact the cerebral pharmacokinetic of numerous drugs and impede their cerebral delivery (Sugiyama et al., 1999; Goncalves et al., 2018).

Differences exist between human and the species used in pharmacotoxicological studies with respect to blood-brain interfaces attributes. These differences bear on the protein composition of tight junctions, as illustrated by claudin-5 whose immunoreactivity was reported in epithelial cell tight junctions of the choroid plexus in human, but not in rat (Mollgard et al., 2017; Virag et al., 2017). They also bear on the level of expression or substrate specificity of many efflux transporters at blood-brain interfaces. Among those differences, the level of ABCG2 protein relative to that of ABCB1 at the BBB is higher in human as compared to rodent, hence the impact of ABCG2 on brain drug delivery relative to that of ABCB1 is likely to be more important in human than in rodent (Shawahna et al., 2011). ABCG2 was reported absent in human and rat choroidal epithelium, but was detected in adult mouse epithelium (reviewed in Strazielle and Ghersi-Egea, 2015). The expression at the BBB of ABCC2, thought to be implicated in the mechanisms underlying resistance to antiepileptic drugs in epileptic patients (Kubota et al., 2006), may also display species specificities (discussed in Kubota et al., 2006; Dauchy et al., 2008). Organic anion-transporting polypeptides (OATPs) encoded by SLCO genes display a high degree of species variability that prevents the straightforward superposition of rodent and human OATP sub-family classification (Hagenbuch and Meier, 2004), and therefore the extrapolation of OATP-dependent transport data acquired in rodent to human.

This variability in the molecular effectors determining barrier functions needs to be considered when animal studies, especially those performed in rodents, are used to predict blood-brain transport processes and cerebral drug pharmacokinetic parameters for human. Non-human primates (NHP), in particular the cynomolgus monkey, have been considered to be more predictive species for neuropharmacological, toxicological and pathophysiological studies than rodents (Bontrop, 2001). Their genetic homology with humans is high, with 97% of the DNA sequences being identical between the two species. In addition, the CSF turnover rates of macaques and humans are very similar, and differ markedly from that of rodents, strengthening the relevance of the NHP model in cerebral pharmacokinetic studies (Barten et al., 2017). Several breeding colonies have been developed, providing access to this relevant model for pharmacokinetic studies. However, the distinctive features of blood-brain interfaces in cynomolgus monkeys have so far not been thoroughly investigated.

The present work provides a comprehensive analysis of the features that differentiate the two main blood-CNS interfaces with respect to their barrier functions in cynomolgus monkeys. We used a combination of immunohistochemistry on brain tissues and targeted RT-qPCR analyses of isolated cerebral microvessels and choroid plexuses to investigate the molecular attributes specifically relevant to the bioavailability of cerebral drugs and environmental compounds, and to neuroprotection, i.e., proteins of the tight junctions, ABC multispecific efflux transporters, and multidrug and toxin extrusion proteins encoded by SLC47, SLC22 and SLCO genes. We favored this approach rather than performing an RNA sequencing analysis in view of the large interindividual variation expected from non-human primates compared to laboratory rodent species. Our study permitted to analyze multiple animals at an acceptable cost and to generate information on the differential localization of barrier attributes between the BBB and the BCSFB. Reports comparing these two interfaces for their neuroprotective attributes in other species are scarce. We previously conducted a similar study centered on tight junction proteins in rat (Kratzer et al., 2012). Other than that, most studies focus only on isolated capillaries or on isolated choroid plexuses. We nonetheless provide a tentative comparison of our data in monkey to those available in the literature for rodent and human.

Methods

Animals

2 juvenile and nine adult cynomolgus monkeys (Macaca fascicularis), imported from Le Tamarinier (Mauritius), or Nafovanny (Vietnam) comprising four males and seven females were included in the study. The animals were part of other studies (Table 1) and were socially housed in primate cages under controlled conditions of humidity, temperature, and light (12-h light/12-h dark cycle, light on at 8.00 a.m.), within a dedicated primate facility. Primate diet was provided daily in amounts appropriate for the size and age of the animals. Fresh fruits were also given to the animals daily, and unsweetened treats were scattered in the litter as part of the Testing Facility Environmental Enrichment Program. Tap water was available ad libitum to each animal. Animal care was supervised by veterinarians experienced in NHP husbandry. Following acceptance of the study design by the IACUC for NHP experiments (National Veterinary School of Lyon, Lyon, France), brains were collected from animals undergoing experiments carried out in accordance to the European Communities Council Directive (2010/63/EU) for the care of laboratory animals. The eleven cynomolgus monkeys and their inclusion in the different aspects of the study are described in Table 1.

Tissue sampling

Animals were euthanized under deep anaesthesia (intramuscular injection of Ketamine and Midazolam) with 4 g of intravenous pentobarbital (Dolethal, Vetoquinol). Brains were collected and quickly immerged in cold HBSS (Gibco^®, Fisher Scientific, France). Lateral ventricle choroid plexuses (LVCP) and fourth ventricle choroid plexuses (4VCP), as well as pieces of meninge-free cortex and cerebellum were collected. Samples collected for gene expression analyses were snap-frozen in liquid nitrogen and kept at −80°C. For immunohistochemistry, additional tissue fragments were snap-frozen in isopentane at −50°C, embedded in Tissue-Tek (Sakura Finetek Europe, Netherland) and stored at −80°C. Other fragments were fixed in RCL2 fixative (Alphelys, France) before paraffin embedding. In two animals, freshly collected cortical gray matter was used for immediate microvessel isolation, or frozen at −80°C for further microvessel isolation.

Microvessel isolation

Brain microvessels were isolated as described previously in details for rats (Gazzin et al., 2008). Briefly, an average of 5 g of cortical tissue was used for each preparation. The tissue was carefully cleaned from meninges and superficial blood vessels prior to microvessel isolation. Minced cortical tissue was homogenized in Krebs-Ringer buffer (KR) by mechanical homogenization, and an aliquot of homogenate was sampled for enzymatic measurement. The preparation was further diluted with KR supplemented with 1% (w/v) bovine serum albumin (BSA) (5/1, v/w of tissue), homogenized, and subjected sequentially to several steps of centrifugation, to a 70 kDa dextran gradient, and to filtration on sieves of decreasing mesh sizes. Microvessels were collected on a 40 µm-mesh sieve in 0.1% BSA-supplemented KR.

Total RNA isolation

Total RNA was prepared from LVCP, 4VCP, cerebral cortex, cerebellum, and brain microvessel fractions using Qiagen RNeasy Micro and Mini kits (Qiagen, Valencia, CA, United States) according to the manufacter’s instructions. Tissue was homogenized in RLT buffer using Soft tissue homogenizing tubes in the Minilys tissue grinder (both from Bertin Technologies, France) prior to the column purification step. Digestion with proteinase K (Qiagen) was performed on choroidal and microvascular samples. All tissues were treated with DNAse as recommended in the kit instructions. RNA was quantified by OD measurement at 260 nm using a NanoDrop spectrophotometer (ThermoScientific, Baltimore, MA, United States) and quality was assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, United States). Only samples with an RNA integrity number above 7.8 were used in the study.

BioChain^® total RNA from cynomolgus monkey peripheral tissues (colon, liver, lung, and kidney) were purchased from Clinisciences (Nanterre, France) to be used as positive control tissues to define PCR conditions. All RNAs were reverse-transcribed using the iScript cDNA Synthesis kit (Bio-Rad, Marnes-la-Coquette, France).

Quantitative PCR

Quantitative polymerase chain reaction (qPCR) was performed using the LightCycler FastStart-DNA Master SYBR Green I kit and the LightCycler^® 2.0.5 Instrument (Roche Diagnostics GmbH, Mannheim, Germany), or the LightCycler^® 480 SYBR Green I Master kit and the LightCycler^® 480 Instrument II (Roche). Primers were designed using NCBI Primer-BLAST or chosen from the NCBI probe bank. They were selected to generate amplicons with a length of 85–200 bp (Table 2). After an initial step of DNA polymerase activation at 95°C for 8 min, the following amplification conditions were used: 45 cycles of denaturation at 95°C for 10 s, annealing for 10 s and extension at 72°C for 10 s. A touchdown protocol was applied by setting the initial annealing temperature at 68°C and decreasing this value by 0.5°C for the next 12 cycles, and running all the remaining annealing steps at 62°. Melting-curve analysis was then performed to verify the amplification of a single product with a specific melting temperature. For genes analyzed using the LightCycler FastStart-DNA Master SYBR Green I kit, MgCl₂ concentration was optimized. A negative PCR control without cDNA was included in all runs. A standard curve was generated for each gene of interest by nonlinear regression analysis of crossing points (threshold cycles, Ct) generated for at least five serial dilutions of a cDNA pool, using the LightCycler^® Software 4.1 and LightCycler^® 480 Software 1.5.1.

Ct values of unknown samples were then used to determine in each sample a relative cDNA concentration of the target gene. Possible sample-to-sample variations in reverse transcription efficiency and in qPCR processing were corrected by normalizing the data to the expression of the gene dolichyl-phosphate N-acetylglucosaminephosphotransferase 1 (DPAGT1).

In order to provide an index of abundance for the different tight junction proteins and transporter gene products, expression levels of all genes were estimated first in a reference sample, arbitrarily chosen as LVCP cynomolgus #2 as follows:where efficiencies of amplification were calculated from the linear part of the standard curves using the LightCycler Software 4.1. The obtained gene values were normalized to CLDN1 value set as 100 after correction for the differences in the size of the amplification products. Then for each target gene, the expression level for each sample was expressed relative to the value of the reference sample.

Histology and immunohistochemistry

Hematoxylin (Biolyon 0942)–phloxin (Ral diagnostics 361470)–safran (BDH Gurr 35093) was used to stain nuclei, cytoplasm and connective tissue, respectively, according to the following sequence. Parafin sections were deparafinized in methylcyclohexane (three times for 5 min), rehydrated through a graded series of ethanol/water solutions (100%–0% of ethanol), and incubated in hematoxylin (0.5% w/v) for 5 min. After a 10-min wash in running water, sections were immersed for 15 s in hydrochloric alcool (3 drops of pure hydrochloric acid in 100 mL of absolute ethanol). After a 10-min wash in running water, sections were immersed for 3 s in phloxin (1% w/v). The slides were then immersed for 10 s in an alcoholic safran solution before being rinsed in 100% ethanol. Sections were rinsed quickly with water before being dehydrated through a graded series of ethanol/water solutions (70%–100% ethanol) followed by 3 baths of methylcyclohexane. Sections were examined with an Axioplan microscope (Zeiss, France).

For immunofluorescence labelling, frozen sections were fixed differently depending on the primary antibodies (Table 3). Fixation in 4% (w/v) paraformaldehyde in phosphate buffer was performed at room temperature for 10 min. Fixation in 1% (w/v) paraformaldehyde in phosphate buffer was performed at room temperature for 30 s. Fixation in methanol/acetone (50/50, v/v) was performed at −20°C for 5 min. Fixation in acetone was performed at −20°C for 8 min. Fixed sections were blocked for 1 h at room temperature in phosphate buffer saline (PBS, Euromedex, France) containing 0.2% BSA w/v, 10% normal goat serum v/v, 0.3% Triton X100 v/v for claudins (CLDN-1, -2, -3, -4, and -5). For all other primary antibodies, sections were blocked in a solution containing 5% BSA, 5% normal goat serum, 0.3% Triton X-100 in PBS. Sections were incubated overnight at 4°C in the blocking solution containing the primary antibody. The list of primary antibodies, with company names, product references and final concentrations is given in Table 3. Following three washes in the blocking solution, the sections were incubated with a secondary anti-rabbit, anti-rat or anti-mouse Alexa-conjugated antibody (Invitrogen, 2 μg/mL in blocking solution) for 1 h at room temperature. Nuclei were stained with 4′,6-Diamidine-2′-phenylindole dihydrochloride (Roche, 5 μg/mL in PBS) for 10 min at room temperature and sections were mounted with fluorescence mounting medium (F/TA-030-FM, Thermo Scientific). Negative controls were performed by omitting the primary antibody. Fluorescent immunolabelling was observed using an Axio Imager M2 fluorescence microscope (Zeiss).

Enzymatic activities

Gamma-glutamyltransferase activity was determined in tissue homogenates and microvessel preparations using a dual-beam Cary 100 spectrophotometer (Varian) with L-γ-glutamyl-3-carboxy-4-nitroanilide as a substrate, in the presence of glycylglycine and Triton X-100, as previously described (Ghersi-Egea et al., 1994). The specific activity was calculated using an extinction coefficient of 9900 M^-1.cm^-1 for carboxy 4-nitoaniline. Glutathione-S-transferase activity was measured by kinetic spectrophotometry in the Cary 100 spectrophotometer using 1-chloro-2,4-dinitrobenzene (Sigma), a multispecific substrate of glutathione-S-transferase isoenzymes, as previously described (Ghersi-Egea et al., 2006). The specific activity was calculated using an extinction coefficient of 9600 M^-1.cm^-1 for the glutathione conjugate. Total protein content was measured by the method of Peterson (Peterson, 1977) using BSA to generate the standard curve.

Statistics

Considering the number of structures (choroidal tissue, isolated microvessels, cerebral and cerebellar parenchyma), and the variable number of samples per tissue (n = 3 for isolated microvessels), the expression levels of barrier-related molecular attributes were compared among the different cerebral tissues by the non-parametric Kruskal and Wallis test corrected for multiple comparisons by the false discovery rate method of Benjamin and Hachberg (PRISM software). For clarity, only statistical differences discussed in the result section are marked on Figures 2, 4, 6. The complete set of statistic data is found in Supplementary Table S1. In all figures and in Supplementary Table S1, *, and ** indicate discoveries (statistical differences) when Q was set at 0.05, and 0.01, respectively. q Values close to significance when Q was set at 0.05 are also reported.

Results and discussion

Quality of isolated microvessel and choroid plexus preparations

The brain microvessel isolation technique established for the rat (Gazzin et al., 2008) was applied to the cynomolgus monkey. It produced preparations that were highly enriched in capillaries and virtually devoid of tissue microfragments (Figure 1A). The activity of γ-glutamyltransferase, a key enzyme of the glutathione cycle used as a marker of cerebral endothelial cells (Ghersi-Egea et al., 1987), was enriched on average 40 times in microvessel homogenates compared to the initial cortex homogenates (Figure 1B). Of note, activities measured in both the microvessel fraction and cerebral cortex of cynomolgus were twice those measured in rat preparations (data not shown), indicating that glutathione-dependent metabolic pathways may be especially active in cynomolgus monkey brain. Isolated microvessels also comprise pericytes as they are embedded in a common basal membrane with endothelial cells. As a result, the expression of PDGFRβ¹, a marker of pericytes, was increased 3.8 ± 0.9-fold (n = 3 p < 0.01, paired t-test) in capillaries versus initial whole brain tissue. In contrast, while astrocytic end-feet ghosts can remain occasionally attached to isolated capillaries, mRNA from glial origin was low in the microvessel preparations, exemplified by GFAP mRNA level which was only 7.1 ± 4.8% of the levels measured in corresponding whole brain tissue (n = 3, p < 0.05, paired t-test). Choroid plexuses were microdissected from the lateral and fourth ventricles of cynomolgus monkey brains. Choroid plexuses from the two locations were kept separated for the analyses. Although closely related, they may not share the same level of neuroprotective capacity. Conventional histology showed a preserved organization of the choroidal villi with a well-preserved epithelial layer surrounding the vascularized stroma (Figure 1C). Total RNA from choroidal tissue, isolated microvessels, cortical and cerebellar parenchyma were isolated, reverse transcribed and subjected to qPCR. All mRNA preparations used in this study were assessed for quality (see method). As expected, the choroidal epithelial marker transthyretin was expressed at a high level in the choroid plexuses (Figure 1D), and was undetected in cortical and cerebellar parenchyma. Three microvessel fractions were incorporated in the qRT-PCR analyses as they yielded mRNA of good quality. They were obtained from two different cortical tissue pieces of cynomolgus #7 (2 preparations) and one cortical piece of cynomolgus #8 (1 preparation). The purity of these microvessels was illustrated by the expression of the endothelial marker PECAM-1 which was enriched 30 times in comparison to the initial cortical tissue used for capillary isolation (n = 2). These isolated cynomolgus monkey microvessel and choroid plexus preparations were therefore validated for further characterization of the molecular determinants responsible for the barrier phenotype of blood-brain interfaces.

FIGURE 1

Composition of tight junctions at the blood-brain and blood-CSF barrier

Figure 2 shows the relative mRNA levels of claudins and occludin in cerebral microvessels and choroid plexuses. Data were obtained from juvenile and young adult females (3.3- to 4.6-year-old) with one adult and one older male (5- and 9-year-old, respectively, distinguished on the graphs) incorporated in the study. We combined all data from males and females in the statistical analyses. Of note, we could not evidence any correlation between expression and age when analysing juvenile and adult animals. The 9-year-old male animal yielded a mildly lower than average level of expression for four tight junction proteins in the choroid plexuses.

The molecular composition of tight junctions in cynomolgus monkey blood-brain interfaces shared the following features with that of tight junctions in rat and human barriers we described in Kratzer et al. (2012): CLDN2, 1, 19 (described in rat only), and CLDN3 (by order of abundance), which are hallmarks of the BCSFB, were specifically enriched in both LVCP and 4VCP, while CLDN5, characteristic of the BBB, was highly expressed and enriched in microvessels (Figure 2, blue and orange graphs). The junctional localization of these various proteins was confirmed by immunohistochemistry on monkey choroidal and parenchymal tissue (Figures 3A,B,F). OCLN coding for Occludin was highly expressed in both barrier fractions (Figure 2, green graph). CLDN11 was mostly expressed in parenchymal tissue (Figure 2, black graph), as expected from its involvement in myelin sheet organization, and as we already reported for adult rat brain parenchyma (Kratzer et al., 2012).

FIGURE 2

FIGURE 3

Of note, we found that CLDN7 and CLDN23 mRNAs were enriched in the cynomolgus monkey microvessel and choroid plexus preparations, respectively. Cldn-7 may play a role in tight junction repair at the BBB as inferred from the recent study performed on kidney epithelial cells (Higashi et al., 2023). The relative distribution of these two claudins between the two interfaces has not been reported previously in any species. We detected mRNAs for tight junction-associated ZO-1 and ZO-2 in all tissues tested, with no clear enrichment in either the cerebral microvessels or choroid plexuses (Supplementary Figure S1).

This study also provided evidence for a number of differences in the composition of tight junctions in cynomolgus monkey compared to the rat (Kratzer et al., 2012).

The localization of CLDN-4, selectively expressed at the BBB in rat (Kratzer et al., 2012), was confirmed in cynomolgus monkey (Figure 3E), but the mRNA analysis revealed that in the NHP, CLDN4 is also expressed in the choroidal tissue (Figure 2), as observed in human choroid plexuses (Rodriguez-Lorenzo et al., 2020). CLDN16 mRNA, selectively enriched at the BBB in rat (Kratzer et al., 2012), was further enriched in choroid plexuses of cynomolgus monkey. CLDN22 mRNA, selectively enriched at the BCSFB in rat (Kratzer et al., 2012), was also expressed at the BBB in the cynomolgus monkeys (Figure 2).

CLDN-3, selectively expressed and immunoreactive in the BCSFB in rat (Kratzer et al., 2012), was detected by immunohistochemistry at both interfaces in cynomolgus monkey (Figures 3C,D). We also observed in cynomolgus monkey additional CLDN-1 immunoreactivity in inter-endothelial junctions of cortical microvessels and larger vessels (data not shown), an observation previously reported for human (Tran et al., 2016). The expression of CLDN-3 at the BBB is debated and may vary between species (Kratzer et al., 2012; Steinemann et al., 2016; Tran et al., 2016). Given the low level of CLDN3 mRNA measured in the monkey microvessels compared to the level in choroid plexuses, and the absence of detection of CLDN1 mRNA in the microvessel fraction (Figure 2), these two claudins, if present at the cynomolgus monkey BBB, are probably only marginally expressed. Although anti-claudin antibodies are claudin-specific, a cross-reactivity between CLDN-1 or CLDN-3 and other tight junction proteins at the cerebral capillaries may occur, as reported for Cldn-3 in mice (Castro Dias et al., 2019). The parenchymal expression of CLDN3 restricted to the cerebellum remains also to be understood (Figure 2). Yet, a potential contamination of the cerebellar tissues by appended 4VCP fragments was ruled out by the complete absence of transthyretin expression in these preparations. A robust CLDN-5 immunoreactivity was observed in cynomolgus monkey, not only at the BBB and in endothelial junctions of large choroidal vessels as observed previously in rats (Kratzer et al., 2012), but also in junctions between choroidal epithelial cells (Figures 3G,H). The latter labelling has not been observed in the rat choroidal tissue, but has been observed in the choroidal epithelium during human development (Mollgard et al., 2017; Virag et al., 2017). Using RNA sequencing of adult human CPs, Rodriguez-Lorenzo and colleagues showed a substantial CLDN5 expression in this tissue (Rodriguez-Lorenzo et al., 2020), but did not assess CLDN-5 localization in their study. Collectively, these observations call for a clear understanding of the exact contribution of the numerous tightening (e.g., CLDN-5) and pore-forming (e.g., CLDN-2) claudins present at the BCSFB in setting the fence function of this interface. Differences in tight junction proteins between species may change the function of epithelial junctions and subsequently modify selectively blood to CSF permeation.

Taken together, our data indicate that the blood-brain and blood-CSF barriers in cynomolgus monkey share more analogy with the human barriers than the rodent barriers with regard to the protein composition of their tight junctions.

Expression of drug efflux ABC transporters at the blood-brain and blood-CSF barriers

ABCB1 and ABCG2

Among ABC transporters involved in the efflux of drugs, both ABCB1 and ABCG2 genes were expressed at much higher levels in monkey brain microvessel preparations in comparison to the choroid plexuses (Figure 4, orange graphs), as described in all other mammalian species so far. Immunoreactivity of the corresponding proteins in brain vessels demonstrated a luminal localization (Figures 5A–C), as already observed in rat and human by different groups (Dauchy et al., 2008; Gazzin et al., 2008). The level of ABCG2 mRNA was substantially higher than that of ABCB1 in cynomolgus monkey brain microvessels (Figure 4, note scale differences). This superior level of ABCG2 expression was already observed in human, albeit to a lesser degree (Dauchy et al., 2008). Proteomic analyses performed on microvessels isolated from marmoset (Hoshi et al., 2013) and cynomolgus monkey (Ito et al., 2011) brains indicated that the difference in transcript levels of the two genes we observed in monkey is reflected at the protein level. In contrast, protein levels of ABCB1 seem higher than those of ABCG2 in rats (Ito et al., 2011; Hoshi et al., 2013; Omori et al., 2020). Some proteomic studies highlighted a higher level of ABCG2 protein as compared to ABCB1 protein in microvessels isolated from human brain (Shawahna et al., 2011; Billington et al., 2019; Bao et al., 2020; Storelli et al., 2021), while other studies did not confirm this difference (Uchida et al., 2011; Al-Majdoub et al., 2019). A larger implication of ABCG2 over ABCB1 in controlling cerebral efflux processes at the human BBB would have pharmacological and pathophysiological significance as ABCG2 and ABCB1 have different, although partially overlapping, substrate specificities (Choi and Yu, 2014), and different substrate affinities (Hegedus et al., 2009). For instance, ABCB1 rather than ABCG2 is likely involved in amyloid β peptide efflux from the brain (Wolf et al., 2012).

FIGURE 4

FIGURE 5

In the choroidal tissue of cynomolgus monkeys, we found a very low expression of ABCB1 (Figure 4). ABCB1 mRNA was identified in human CP (Rodriguez-Lorenzo et al., 2020), but protein levels have been shown to be very low in both rat and human choroidal tissues (Gazzin et al., 2008). Accordingly, we could not immunodetect ABCB1 in either epithelial or endothelial cells of monkey CP. ABCG2 transcripts were identified in monkey choroid plexus tissues, albeit at low levels by comparison to the level measured in isolated microvessels (Figure 4). In human CP, ABCG2 mRNA was also identified, at low level similar to that of ABCB1 (Rodriguez-Lorenzo et al., 2020). Previous studies reported low and developmentally regulated ABCG2 mRNA levels in rat choroidal tissue (Ek et al., 2010; Kratzer et al., 2013), undetectable ABCG2 transcripts in developing and adult mouse choroidal tissue (Tachikawa et al., 2005), and low but sizable ABCG2 protein levels in membrane fractions isolated from adult rat choroidal tissue (Uchida et al., 2015). Our immunohistological analysis of ABCG2 in monkey choroid plexus failed to detect the transporter in the outer epithelial layer, but located it in the vessel loops irrigating the choroidal villi (Figures 5D–G), a localization also observed in human (Mollgard et al., 2017) and mice (Orford et al., 2009). As epithelial cells constitute a large proportion of the choroidal tissue, this restricted endothelial localization of ABCG2 explains why the expression level we observed in the choroidal tissue as a whole is lower than in isolated microvessels (Figure 4), despite the strong immunohistochemical signal observed in both brain and choroidal endothelia. The apparent luminal localization of ABCG2 (Figure 5E) indicates a transport directionality towards blood, which suggests that the choroidal endothelium is less permissive than previously thought to ABCG2 substrates. Previously published attempts to locate ABCG2 at the choroidal epithelium itself by immunohistochemical analyses generally concluded to the absence of the transporter at this location in adult rat and human. In mouse, the data were conflicting, possibly due to immunohistochemical methodology issues (reviewed in (Matsumoto et al., 2015; Strazielle and Ghersi-Egea, 2015). These published data, coupled to our results showing an immunohistochemical signal restricted to the endothelium in adult cynomolgus monkey, indicate that ABCG2-dependent drug transport at the choroidal epithelium, if existing, is likely limited to the early period of brain development.

ABCC1

The ABCC1 gene was expressed at a higher level in cynomolgus monkey choroid plexuses than in cerebral microvessels (Figure 4, blue graph), and the protein was immunodetected at the basolateral membrane of the choroidal epithelium (Figure 5I). A similar pattern was previously reported for ABCC1 protein in rat and human (Gazzin et al., 2008). In contrast to the consensus on ABCC1 expression and function at the BCSFB, the expression and functional relevance of ABCC1 at the BBB is still debated. Our present data indicate that in cynomolgus monkey, ABCC1 is mainly a blood-CSF rather than a blood-brain barrier component. The expression level of ABCC1 was even higher in cortical and cerebellar tissues than in capillary preparations (Figure 4), a difference in distribution observed neither in rat for the protein (Gazzin et al., 2008), nor in human for mRNA (Dauchy et al., 2008). This may indicate that cells forming the neuropil, especially astrocytes (Gennuso et al., 2004), are an important source of ABCC1 in the brain of cynomolgus monkeys. In line with this result, a vesicular labelling was observed in a large proportion of cortical parenchymal cells in cynomolgus monkey brains by immunofluorescence using an anti-ABCC1 antibody (data not shown).

ABCC4

ABCC4 gene expression was found to be largely enriched in the BCSFB in cynomolgus monkey (Figure 4, blue graph). At this site ABCC4 was exclusively located at the basolateral, blood-facing membrane of the choroidal epithelium (Figure 5J), clearly distinguishable from the apical membrane identified by Na-K-ATPase labelling (Figure 5K). This strictly basolateral localization was previously described in other species (Leggas et al., 2004; Strazielle et al., 2005). We could not detect ABCC4 protein in cynomolgus monkey cerebral cortex by immunohistochemistry, while vessels were labelled in rat sections (data not shown). ABCC4 has been previously localized at both barriers in rodents, where it actively prevented the antitumoral drug topotecan to accumulate in the brain and CSF (Leggas et al., 2004). In this latter study, the increase in topotecan concentration between wild type and knockout mice was however higher in CSF than in brain tissue, suggesting that ABCC4 is especially active at the BCSFB. In human, no ABCC4 mRNA enrichment was observed in cerebral capillaries compared to the cortical tissue, by contrast to the strong enrichment observed for ABCB1 and ABCG2 (Dauchy et al., 2008). Another study showed both at the mRNA and protein level that ABCC4 enrichment in brain capillaries was more prominent in rat than in human (Warren et al., 2009). Thus, the higher expression of ABCC4 at the BCSFB compared to the BBB represents another feature shared by human and non-human primates, that is not observed in rodents. Besides drugs, ABCC4 transports prostaglandin E2 (PGE2), (Reid et al., 2003), a neuroinflammatory modulator which is not inactivated within the brain (Alix et al., 2008), but removed by transport at blood-brain interfaces (Khuth et al., 2005; Akanuma et al., 2010). The species differences in the localisation of ABCC4 at blood-brain interfaces therefore highlight choroid plexuses as the main site for PGE2 signal termination in human and non-human primates. Of note, a strong ABCC4 immunohistochemical signal was also observed at the arachnoid membrane separating the subarachnoid CSF from the dura matter (Figure 5L). Immunohistochemistry data have to be interpreted with caution in these leptomeningeal areas, owing to the frequent nonspecific border effects associated with immunochemical signals at outer brain membranes, and further investigations are needed to confirm the localization of efflux transporters at the arachnoid in primates.

The ABCC1 and/or ABCC4 transporters are likely to be the active carriers exporting into blood the conjugates formed within the choroidal epithelium by the glutathione-S-transferases, thus participating in a cerebral mechanism of toxicant inactivation described in rat and human (Ghersi-Egea et al., 2006; Kratzer et al., 2018). We measured the overall conjugating activity to glutathione in monkey tissues using 1-chloro-2,4-dinitrobenzene as a prototypic substrate. The specific enzymatic activities ranged from 114 to 175 nmol min^-1. mg prot^-1 and 124–273 nmol min^-1. mg prot^-1 in LVCP and 4VCP, respectively (ranges obtained for four animals, two males and two females, with no sizeable sex difference). These choroidal activities were 3–5 times higher than those measured in the cerebral cortex (42-58 nmol min^-1. mg prot^-1, p < 0.01 and 0.05 for LVCP and 4VCP, respectively, two-tailed Student’s t-test for unequal variance). Thus, the coupled metabolic/efflux transport process, which acts in the rat BCSFB as a mechanism of neuroprotection towards toxicants should also be functional in the cynomolgus monkey choroidal barrier.

Expression of other drug efflux transporters at the blood-brain and blood-CSF barriers

Besides ABC efflux transporters, various carriers of the SLC superfamily can also influence the cerebral bio-availability of drugs, toxic compounds, and biologically active metabolites. They include members of the SLCO, SLC22 and SLC47 families, which display distinct substrate specificity profiles.

The present work has focused among all SLCO carriers, on the ubiquitous members SLCO3A1 and SLCO4A1, and the BBB-specific members (within the brain) SLCO2B1 and SLCO1A2 (Bronger et al., 2005; Roth et al., 2012; Ronaldson and Davis, 2013). The OATP proteins encoded by these four genes accept various xenobiotics as substrates, such as antibiotics, endothelin A receptor antagonists, beta-blockers, antiretroviral and antineoplastic agents. Endogenous compounds such as steroids, thyroid hormones, prostaglandins are also transported by these carriers. The SLCO2A1-encoded OATP carrier more specifically transports prostaglandins (for reviews on substrate selectivity of these transporters, see Roth et al., 2012; Ronaldson and Davis, 2013). The expression profile of these transporters in brain barriers and parenchyma of cynomolgus is described in Figure 6. The robust expression of SLCO2B1 and SLCO1A2 genes in the non-human primate BBB, in line with data obtained in human tissues, stresses the probable influence of these two proteins on cerebral drug bioavailability (Morris et al., 2017; Schafer et al., 2020; Kinzi et al., 2021). Both messengers were enriched in microvessels compared to the cortex and cerebellum, corroborating the high microvessel-to-tissue ratios previously reported for mRNA levels in human brain (Gao et al., 2000; Geier et al., 2013; Suhy et al., 2017). Immunohistochemical and quantitative proteomic analyses reported by other groups consistently detected SLCO2B1-encoded protein in microvessels isolated from human brain, while SLCO1A2-encoded protein was not always detected (Uchida et al., 2011; Gao et al., 2015; Billington et al., 2019; Bao et al., 2020; Schafer et al., 2020). In cynomolgus choroid plexuses, we found high mRNA levels of SLCO1A2, but not SLCO2B1 (Figure 6). This is in contrast with human transcriptomic data showing a higher expression of SLCO2B1 as compared to SLCO1A2 in this tissue (Rodriguez-Lorenzo et al., 2020), and with a proteomic study that failed to detect SLCO1A2-encoded protein in one specimen of human choroid plexus tissue (Uchida et al., 2015). The expression of SLCO2A1 and SLCO4A1 genes was low in all cynomolgus tissues we investigated, with no apparent specificity for either barrier. In contrast, SLCO3A1 expression was higher in choroid plexuses than in microvessels isolated from monkey brain, and intermediate in parenchyma (Figure 6). In line with this pattern, immunohistochemical analysis of human brain sections has shown that the two splice variants of human OATO3A1 were associated with the membrane of choroid plexus epithelial cells, and were detected in neural cells of the frontal cortex (Huber et al., 2007). Comparing the expression of these SLCO genes between primate and rodent is strongly impeded by the low homology of sequences between these species, which is characteristic of the SLCO family (Hagenbuch and Meier, 2004). Overall, our data suggest that the expression of SLCO genes of interest in the primate BBB resembles that observed in human, and further provide a detailed pattern of expression for these genes at the BCSFB. Of note, OATP-dependent transport processes can be bidirectional, and the membrane localization of most OATP proteins is unknown in the primate blood-brain and blood-CSF barriers. Whether these transporters influence positively or negatively the cerebral penetration of their substrates remains a poorly understood field of research in primates.

FIGURE 6

The organic anion transporter SLC22A8 has been shown to play an important role as an efflux transporter for many drugs including antivirals and antibiotics, and for endogenous compounds such as steroid derivatives at both brain barriers in rats and mice (Strazielle et al., 2003; Sykes et al., 2004; Ose et al., 2009). We found a high expression of this gene in choroid plexuses isolated from monkey brain, while its expression was barely detectable in other tissues investigated including microvessels (Figure 6). Accordingly, the corresponding protein has not been detected in a quantitative proteomic analysis of microvessels isolated from cynomolgus monkey brains (Ito et al., 2011). In human brain microvessels, the protein was identified in only one study, albeit at a low level compared to ABC transporters (Al-Majdoub et al., 2019), and was not detected in several other targeted proteomic analyses (Shawahna et al., 2011; Uchida et al., 2011; Billington et al., 2019; Bao et al., 2020). SLC22A8 expression level was higher than that of ABCC1 in human CP (Rodriguez-Lorenzo et al., 2020), and the protein was present at a level similar to that of ABCC1 in one sample of human choroid plexus (Uchida et al., 2015). Collectively, these data suggest that, with respect to the relative expression of SC22A8 between the two barriers, a higher similarity of SLC22A8-dependent efflux processes exists between non-human and human primates than between primates and rodents.

Finally, we investigated carriers of the SLC47 family for which differences in expression have been reported between human and non-primate species. The protein multidrug and toxin exclusion (MATE)1 encoded by SLC47A1 was detected in substantial amounts by absolute targeted proteomic in human choroid plexuses, but was under the limit of quantification in rat tissue (Uchida et al., 2015). In cynomolgus monkey, we found that SLC47A1 and SLC47A2 levels of expression were both higher in choroid plexuses than in brain microvessels (Figure 6), a finding that is consistent with the modest expression, if any, of SLC47A1 in human brain microvessels (Shawahna et al., 2011). We also detected SLC47A1 mRNA in monkey cortex and cerebellum, while SLC47A2 expression was more specific of the choroid plexuses (Figure 6). Fairly high levels of message for both transporters were also detected in human choroid plexuses (Rodriguez-Lorenzo et al., 2020). Yet, the protein MATE2-K, the main variant isoform encoded by SLC47A2 in kidney, was under the limit of quantification in human choroid plexus (Uchida et al., 2015). The proteins encoded by SLC47 genes, MATE1 and MATE2-K are proton-coupled antiporters for small organic cations. They accept endogenous and exogenous cations as substrates, including a large range of therapeutic agents, natural products such as flavonoids, and potentially toxic molecules such as creatinine, some neurosteroids, or else methylphenylpyridinium (Motohashi and Inui, 2013; Nies et al., 2016). The substrate specificity of other SLC47A2 variant isoforms is currently unknow except for tetraethylammonium (Nies et al., 2016). More data on the protein isoforms actually present in the BCSFB, their membrane localization, and their substrate specificities are needed before their involvement in the clearance of organic cations from the CNS can be fully clarified in primate.

Conclusions

A summary of the main similarities and differences between cynomolgus monkey, rat, and human in the molecular attributes setting neuroprotective functions at blood-brain interfaces is provided in Table 4. While the main tight junction and drug transport characteristics of brain barriers are shared between mammalian species, the cynomolgus monkey shares with human some differences in the gene expression and barrier distribution of selected claudins and efflux transporters in comparison to rodents. This needs to be kept in mind when designing and interpreting the results of cerebral toxicological and drug delivery studies. Our knowledge of these species differences should also clarify the pathogenic mechanisms which involve changes in the integrity of tight junctions or efflux transporters, such as met in neuroinflammatory and neurodegenerative diseases. An alteration of tight junctions may impact immune cell invasion across an inflamed cerebral endothelium or choroidal epithelium. A dysfunction of efflux transporters can lead to eicosanoid and amyloid β peptide accumulation in the brain. Finally, our analysis provides the first image of drug carriers expression at the primate BCSFB, a mandatory step toward a better control of cerebral drug delivery via the BCSFB.

References

• 1

  AkanumaS.HosoyaK.ItoS.TachikawaM.TerasakiT.OhtsukiS. (2010). Involvement of multidrug resistance-associated protein 4 in efflux transport of prostaglandin E(2) across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. J. Pharmacol. Exp. Ther.333 (3), 912–919. 10.1124/jpet.109.165332

  • CrossRef
  • Google Scholar
  • View reference in article

• 2

  AlixE.SchmittC.StrazielleN.Ghersi-EgeaJ. F. (2008). Prostaglandin E2 metabolism in rat brain: role of the blood-brain interfaces. Cerebrospinal Fluid Res.5, 5. 10.1186/1743-8454-5-5

  • CrossRef
  • Google Scholar
  • View reference in article

• 3

  Al-MajdoubZ. M.Al FeteisiH.AchourB.WarwoodS.NeuhoffS.Rostami-HodjeganA.et al (2019). Proteomic quantification of human blood-brain barrier SLC and ABC transporters in healthy individuals and dementia patients. Mol. Pharm.16 (3), 1220–1233. 10.1021/acs.molpharmaceut.8b01189

  • CrossRef
  • Google Scholar
  • View reference in article

• 4

  BaoX.WuJ.XieY.KimS.MichelhaughS.JiangJ.et al (2020). Protein expression and functional relevance of efflux and uptake drug transporters at the blood-brain barrier of human brain and glioblastoma. Clin. Pharmacol. Ther.107 (5), 1116–1127. 10.1002/cpt.1710

  • CrossRef
  • Google Scholar
  • View reference in article

• 5

  BartenD. M.CadelinaG. W.WeedM. R. (2017). Dosing, collection, and quality control issues in cerebrospinal fluid research using animal models. Handb. Clin. Neurol.146, 47–64. 10.1016/B978-0-12-804279-3.00004-6

  • CrossRef
  • Google Scholar
  • View reference in article

• 6

  BillingtonS.SalphatiL.HopC.ChuX.EversR.BurdetteD.et al (2019). Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics. Clin. Pharmacol. Ther.106 (1), 228–237. 10.1002/cpt.1373

  • CrossRef
  • Google Scholar
  • View reference in article

• 7

  BontropR. E. (2001). Non-human primates: essential partners in biomedical research. Immunol. Rev.183, 5–9. 10.1034/j.1600-065x.2001.1830101.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 8

  BrongerH.KonigJ.KopplowK.SteinerH. H.AhmadiR.Herold-MendeC.et al (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res.65 (24), 11419–11428. 10.1158/0008-5472.CAN-05-1271

  • CrossRef
  • Google Scholar
  • View reference in article

• 9

  Castro DiasM.CoisneC.LazarevicI.BadenP.HataM.IwamotoN.et al (2019). Claudin-3-deficient C57BL/6J mice display intact brain barriers. Sci. Rep.9 (1), 203. 10.1038/s41598-018-36731-3

  • CrossRef
  • Google Scholar
  • View reference in article

• 10

  ChoiY. H.YuA. M. (2014). ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr. Pharm. Des.20 (5), 793–807. 10.2174/138161282005140214165212

  • CrossRef
  • Google Scholar
  • View reference in article

• 11

  DauchyS.DutheilF.WeaverR. J.ChassouxF.Daumas-DuportC.CouraudP. O.et al (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem.107 (6), 1518–1528. 10.1111/j.1471-4159.2008.05720.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 12

  EkC. J.WongA.LiddelowS. A.JohanssonP. A.DziegielewskaK. M.SaundersN. R. (2010). Efflux mechanisms at the developing brain barriers: ABC-transporters in the fetal and postnatal rat. Toxicol. Lett.197 (1), 51–59. 10.1016/j.toxlet.2010.04.025

  • CrossRef
  • Google Scholar
  • View reference in article

• 13

  GaoB.HagenbuchB.Kullak-UblickG. A.BenkeD.AguzziA.MeierP. J. (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther.294 (1), 73–79. 10.1016/s0022-3565(24)39041-x

  • CrossRef
  • Google Scholar
  • View reference in article

• 14

  GaoB.VavrickaS. R.MeierP. J.StiegerB. (2015). Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch.467 (7), 1481–1493. 10.1007/s00424-014-1596-x

  • CrossRef
  • Google Scholar
  • View reference in article

• 15

  GazzinS.StrazielleN.SchmittC.Fevre-MontangeM.OstrowJ. D.TiribelliC.et al (2008). Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J. Comp. Neurol.510 (5), 497–507. 10.1002/cne.21808

  • CrossRef
  • Google Scholar
  • View reference in article

• 16

  GeierE. G.ChenE. C.WebbA.PappA. C.YeeS. W.SadeeW.et al (2013). Profiling solute carrier transporters in the human blood-brain barrier. Clin. Pharmacol. Ther.94 (6), 636–639. 10.1038/clpt.2013.175

  • CrossRef
  • Google Scholar
  • View reference in article

• 17

  GennusoF.FernettiC.TiroloC.TestaN.L'EpiscopoF.CanigliaS.et al (2004). Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proc. Natl. Acad. Sci. U. S. A.101 (8), 2470–2475. 10.1073/pnas.0308452100

  • CrossRef
  • Google Scholar
  • View reference in article

• 18

  Ghersi-EgeaJ. F.Leninger-MullerB.SulemanG.SiestG.MinnA. (1994). Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs. J. Neurochem.62 (3), 1089–1096. 10.1046/j.1471-4159.1994.62031089.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 19

  Ghersi-EgeaJ. F.MinnA.SiestG. (1987). Changes of cerebral gamma glutamyltransferase activities after treatment with exogenous inducers. Neurochem. Res.12 (4), 357–359. 10.1007/BF00993245

  • CrossRef
  • Google Scholar
  • View reference in article

• 20

  Ghersi-EgeaJ. F.StrazielleN.MuratA.JouvetA.BuenerdA.BelinM. F. (2006). Brain protection at the blood-cerebrospinal fluid interface involves a glutathione-dependent metabolic barrier mechanism. J. Cereb. Blood Flow. Metab.26 (9), 1165–1175. 10.1038/sj.jcbfm.9600267

  • CrossRef
  • Google Scholar
  • View reference in article

• 21

  GoncalvesJ.BickerJ.AlvesG.FortunaA.FalcaoA. (2018). Relevance of breast cancer resistance protein to brain distribution and central acting drugs: a pharmacokinetic perspective. Curr. Drug Metab.19 (12), 1021–1041. 10.2174/1389200219666180629121033

  • CrossRef
  • Google Scholar
  • View reference in article

• 22

  HagenbuchB.MeierP. J. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch.447 (5), 653–665. 10.1007/s00424-003-1168-y

  • CrossRef
  • Google Scholar
  • View reference in article

• 23

  HegedusC.Ozvegy-LaczkaC.ApatiA.MagocsiM.NemetK.OrfiL.et al (2009). Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol.158 (4), 1153–1164. 10.1111/j.1476-5381.2009.00383.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 24

  HigashiT.SaitoA. C.FukazawaY.FuruseM.HigashiA. Y.OnoM.et al (2023). EpCAM proteolysis and release of complexed claudin-7 repair and maintain the tight junction barrier. J. Cell Biol.222 (1), e202204079. 10.1083/jcb.202204079

  • CrossRef
  • Google Scholar
  • View reference in article

• 25

  HoshiY.UchidaY.TachikawaM.InoueT.OhtsukiS.TerasakiT. (2013). Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J. Pharm. Sci.102 (9), 3343–3355. 10.1002/jps.23575

  • CrossRef
  • Google Scholar
  • View reference in article

• 26

  HuberR. D.GaoB.Sidler PfandlerM. A.Zhang-FuW.LeutholdS.HagenbuchB.et al (2007). Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am. J. Physiol. Cell Physiol.292 (2), C795–C806. 10.1152/ajpcell.00597.2005

  • CrossRef
  • Google Scholar
  • View reference in article

• 27

  HubertV.ChauveauF.DumotC.OngE.BernerL. P.Canet-SoulasE.et al (2019). Clinical imaging of choroid plexus in Health and in brain disorders: a mini-review. Front. Mol. Neurosci.12, 34. 10.3389/fnmol.2019.00034

  • CrossRef
  • Google Scholar
  • View reference in article

• 28

  ItoK.UchidaY.OhtsukiS.AizawaS.KawakamiH.KatsukuraY.et al (2011). Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J. Pharm. Sci.100 (9), 3939–3950. 10.1002/jps.22487

  • CrossRef
  • Google Scholar
  • View reference in article

• 29

  KhuthS. T.StrazielleN.GiraudonP.BelinM. F.Ghersi-EgeaJ. F. (2005). Impairment of blood-cerebrospinal fluid barrier properties by retrovirus-activated T lymphocytes: reduction in cerebrospinal fluid-to-blood efflux of prostaglandin E2. J. Neurochem.94(6), 1580–1593. 10.1111/j.1471-4159.2005.03309.x

  • CrossRef
  • Google Scholar
  • View reference in article

• 30

  KinziJ.GrubeM.Meyer Zu SchwabedissenH. E. (2021). OATP2B1 - the underrated member of the organic anion transporting polypeptide family of drug transporters?Biochem. Pharmacol.188, 114534. 10.1016/j.bcp.2021.114534

  • CrossRef
  • Google Scholar
  • View reference in article

• 31

  KratzerI.LiddelowS. A.SaundersN. R.DziegielewskaK. M.StrazielleN.Ghersi-EgeaJ. F. (2013). Developmental changes in the transcriptome of the rat choroid plexus in relation to neuroprotection. Fluids Barriers CNS10 (1), 25. 10.1186/2045-8118-10-25

  • CrossRef
  • Google Scholar
  • View reference in article

• 32

  KratzerI.StrazielleN.SaudraisE.MonkkonenK.MallevalC.BlondelS.et al (2018). Glutathione conjugation at the blood-CSF barrier efficiently prevents exposure of the developing brain fluid environment to blood-borne reactive electrophilic substances. J. Neurosci.38 (14), 3466–3479. 10.1523/JNEUROSCI.2967-17.2018

  • CrossRef
  • Google Scholar

• 33

  KratzerI.VasiljevicA.ReyC.Fevre-MontangeM.SaundersN.StrazielleN.et al (2012). Complexity and developmental changes in the expression pattern of claudins at the blood-CSF barrier. Histochem Cell Biol.138 (6), 861–879. 10.1007/s00418-012-1001-9

  • CrossRef
  • Google Scholar

• 34

  KubotaH.IshiharaH.LangmannT.SchmitzG.StiegerB.WieserH. G.et al (2006). Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res.68 (3), 213–228. 10.1016/j.eplepsyres.2005.11.011

  • CrossRef
  • Google Scholar

• 35

  LeggasM.AdachiM.SchefferG. L.SunD.WielingaP.DuG.et al (2004). Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell Biol.24 (17), 7612–7621. 10.1128/MCB.24.17.7612-7621.2004

  • CrossRef
  • Google Scholar

• 36

  MatsumotoK.ChibaY.FujiharaR.KuboH.SakamotoH.UenoM. (2015). Immunohistochemical analysis of transporters related to clearance of amyloid-β peptides through blood-cerebrospinal fluid barrier in human brain. Histochem Cell Biol.144 (6), 597–611. 10.1007/s00418-015-1366-7

  • CrossRef
  • Google Scholar

• 37

  MollgardK.DziegielewskaK. M.HolstC. B.HabgoodM. D.SaundersN. R. (2017). Brain barriers and functional interfaces with sequential appearance of ABC efflux transporters during human development. Sci. Rep.7 (1), 11603. 10.1038/s41598-017-11596-0

  • CrossRef
  • Google Scholar

• 38

  MorrisM. E.Rodriguez-CruzV.FelmleeM. A. (2017). SLC and ABC transporters: expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers. AAPS J.19 (5), 1317–1331. 10.1208/s12248-017-0110-8

  • CrossRef
  • Google Scholar

• 39

  MotohashiH.InuiK. (2013). Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J.15 (2), 581–588. 10.1208/s12248-013-9465-7

  • CrossRef
  • Google Scholar

• 40

  NiesA. T.DammeK.KruckS.SchaeffelerE.SchwabM. (2016). Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Arch. Toxicol.90 (7), 1555–1584. 10.1007/s00204-016-1728-5

  • CrossRef
  • Google Scholar

• 41

  OmoriK.TachikawaM.HiroseS.TaiiA.AkanumaS. I.HosoyaK. I.et al (2020). Developmental changes in transporter and receptor protein expression levels at the rat blood-brain barrier based on quantitative targeted absolute proteomics. Drug Metab. Pharmacokinet.35 (1), 117–123. 10.1016/j.dmpk.2019.09.003

  • CrossRef
  • Google Scholar

• 42

  OrfordM.MeanR.LapathitisG.GenethliouN.PanayiotouE.PanayiH.et al (2009). Generation of an ABCG2(GFPn-puro) transgenic line--a tool to study ABCG2 expression in mice. Biochem. Biophys. Res. Commun.384 (2), 199–203. 10.1016/j.bbrc.2009.04.089

  • CrossRef
  • Google Scholar

• 43

  OseA.ItoM.KusuharaH.YamatsuguK.KanaiM.ShibasakiM.et al (2009). Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab. Dispos.37 (2), 315–321. 10.1124/dmd.108.024018

  • CrossRef
  • Google Scholar

• 44

  PetersonG. L. (1977). A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem.83 (2), 346–356. 10.1016/0003-2697(77)90043-4

  • CrossRef
  • Google Scholar

• 45

  ReidG.WielingaP.ZelcerN.van der HeijdenI.KuilA.de HaasM.et al (2003). The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. U. S. A.100 (16), 9244–9249. 10.1073/pnas.1033060100

  • CrossRef
  • Google Scholar

• 46

  Rodriguez-LorenzoS.Ferreira FranciscoD. M.VosR.van Het HofB.RijnsburgerM.SchrotenH.et al (2020). Altered secretory and neuroprotective function of the choroid plexus in progressive multiple sclerosis. Acta Neuropathol. Commun.8 (1), 35. 10.1186/s40478-020-00903-y

  • CrossRef
  • Google Scholar

• 47

  RonaldsonP. T.DavisT. P. (2013). Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol. Rev.65 (1), 291–314. 10.1124/pr.112.005991

  • CrossRef
  • Google Scholar

• 48

  RothM.ObaidatA.HagenbuchB. (2012). OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol.165 (5), 1260–1287. 10.1111/j.1476-5381.2011.01724.x

  • CrossRef
  • Google Scholar

• 49

  SchaferA. M.Meyer Zu SchwabedissenH. E.Bien-MollerS.HubenyA.VogelgesangS.OswaldS.et al (2020). OATP1A2 and OATP2B1 are interacting with dopamine-receptor agonists and antagonists. Mol. Pharm.17 (6), 1987–1995. 10.1021/acs.molpharmaceut.0c00159

  • CrossRef
  • Google Scholar

• 50

  ShawahnaR.UchidaY.DeclevesX.OhtsukiS.YousifS.DauchyS.et al (2011). Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm.8 (4), 1332–1341. 10.1021/mp200129p

  • CrossRef
  • Google Scholar

• 51

  SteinemannA.GalmI.ChipS.NitschC.MalyI. P. (2016). Claudin-1, -2 and -3 are selectively expressed in the epithelia of the choroid plexus of the mouse from early development and into adulthood while claudin-5 is restricted to endothelial cells. Front. Neuroanat.10, 16. 10.3389/fnana.2016.00016

  • CrossRef
  • Google Scholar

• 52

  StorelliF.BillingtonS.KumarA. R.UnadkatJ. D. (2021). Abundance of P-glycoprotein and other drug transporters at the human blood-brain barrier in alzheimer's disease: a quantitative targeted proteomic study. Clin. Pharmacol. Ther.109 (3), 667–675. 10.1002/cpt.2035

  • CrossRef
  • Google Scholar

• 53

  StrazielleN.BelinM. F.Ghersi-EgeaJ. F. (2003). Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters. AIDS17 (10), 1473–1485. 10.1097/00002030-200307040-00008

  • CrossRef
  • Google Scholar

• 54

  StrazielleN.Ghersi-EgeaJ. F. (2013). Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol. Pharm.10 (5), 1473–1491. 10.1021/mp300518e

  • CrossRef
  • Google Scholar

• 55

  StrazielleN.Ghersi-EgeaJ. F. (2015). Efflux transporters in blood-brain interfaces of the developing brain. Front. Neurosci.9, 21. 10.3389/fnins.2015.00021

  • CrossRef
  • Google Scholar

• 56

  StrazielleN.MutinM.Ghersi-EgeaJ. F. (2005). The choroid plexuses: a dynamic interface between the blood and the cerebrospinal fluid. Morphologie89 (285), 90–101. 10.1016/s1286-0115(05)83244-8

  • CrossRef
  • Google Scholar

• 57

  SugiyamaY.KusuharaH.SuzukiH. (1999). Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: importance in the drug delivery to the brain. J. Control Release62 (1-2), 179–186. 10.1016/s0168-3659(99)00036-x

  • CrossRef
  • Google Scholar

• 58

  SuhyA. M.WebbA.PappA. C.GeierE. G.SadeeW. (2017). Expression and splicing of ABC and SLC transporters in the human blood-brain barrier measured with RNAseq. Eur. J. Pharm. Sci.103, 47–51. 10.1016/j.ejps.2017.02.010

  • CrossRef
  • Google Scholar

• 59

  SweeneyM. D.ZhaoZ.MontagneA.NelsonA. R.ZlokovicB. V. (2019). Blood-brain barrier: from physiology to disease and back. Physiol. Rev.99 (1), 21–78. 10.1152/physrev.00050.2017

  • CrossRef
  • Google Scholar

• 60

  SykesD.SweetD. H.LowesS.NigamS. K.PritchardJ. B.MillerD. S. (2004). Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am. J. Physiol. Ren. Physiol.286 (5), F972–F978. 10.1152/ajprenal.00356.2003

  • CrossRef
  • Google Scholar

• 61

  TachikawaM.WatanabeM.HoriS.FukayaM.OhtsukiS.AsashimaT.et al (2005). Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J. Neurochem.95(1), 294–304. 10.1111/j.1471-4159.2005.03369.x

  • CrossRef
  • Google Scholar

• 62

  TranK. A.ZhangX.PredescuD.HuangX.MachadoR. F.GothertJ. R.et al (2016). Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis. Circulation133 (2), 177–186. 10.1161/CIRCULATIONAHA.115.015982

  • CrossRef
  • Google Scholar

• 63

  UchidaY.OhtsukiS.KatsukuraY.IkedaC.SuzukiT.KamiieJ.et al (2011). Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem.117 (2), 333–345. 10.1111/j.1471-4159.2011.07208.x

  • CrossRef
  • Google Scholar

• 64

  UchidaY.ZhangZ.TachikawaM.TerasakiT. (2015). Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen. J. Neurochem.134 (6), 1104–1115. 10.1111/jnc.13147

  • CrossRef
  • Google Scholar

• 65

  ViragJ.HaberlerC.BaksaG.PiurkoV.HegedusZ.ReinigerL.et al (2017). Region specific differences of claudin-5 expression in pediatric intracranial ependymomas: potential prognostic role in supratentorial cases. Pathol. Oncol. Res.23 (2), 245–252. 10.1007/s12253-016-0084-3

  • CrossRef
  • Google Scholar

• 66

  WarrenM. S.ZerangueN.WoodfordK.RobertsL. M.TateE. H.FengB.et al (2009). Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol. Res.59 (6), 404–413. 10.1016/j.phrs.2009.02.007

  • CrossRef
  • Google Scholar

• 67

  WolfA.BauerB.HartzA. M. (2012). ABC transporters and the alzheimer's disease enigma. Front. Psychiatry3, 54. 10.3389/fpsyt.2012.00054

  • CrossRef
  • Google Scholar